Toll Free: 1-888-928-9744

Fibromyalgia - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibromyalgia - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Fibromyalgia - Pipeline Review, H1 2016', provides an overview of the Fibromyalgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fibromyalgia - The report reviews pipeline therapeutics for Fibromyalgia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fibromyalgia therapeutics and enlists all their major and minor projects - The report assesses Fibromyalgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fibromyalgia Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fibromyalgia Overview 8 Therapeutics Development 9 Pipeline Products for Fibromyalgia - Overview 9 Pipeline Products for Fibromyalgia - Comparative Analysis 10 Fibromyalgia - Therapeutics under Development by Companies 11 Fibromyalgia - Therapeutics under Investigation by Universities/Institutes 12 Fibromyalgia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Fibromyalgia - Products under Development by Companies 16 Fibromyalgia - Products under Investigation by Universities/Institutes 17 Fibromyalgia - Companies Involved in Therapeutics Development 18 Astellas Pharma Inc. 18 Daiichi Sankyo Company, Limited 19 Kineta, Inc. 20 Merck & Co., Inc. 21 Premier Biomedical Inc. 22 SWITCH Biotech LLC 23 Theravance Biopharma, Inc. 24 Tonix Pharmaceuticals Holding Corp. 25 Zynerba Pharmaceuticals, Inc. 26 Fibromyalgia - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (celecoxib + famciclovir) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 AS-1069562 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ASP-0819 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ASP-8062 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 AXIBU-04 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 coenzyme Q10+ cyanocobalamin + cyclobenzaprine hydrochloride + naltrexone + pyridoxine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 mirogabalin besylate - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 mirtazapine ODT - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 naltrexone hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules for Fibromyalgia - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SWT-06101 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 TD-9855 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 TNX-102 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 U-2902 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ZYN-001 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Fibromyalgia - Recent Pipeline Updates 58 Fibromyalgia - Dormant Projects 68 Fibromyalgia - Discontinued Products 70 Fibromyalgia - Product Development Milestones 71 Featured News & Press Releases 71 Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia 71 Nov 10, 2015: Tonix Pharmaceuticals Presents Additional Data on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting 71 Oct 01, 2015: Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting 72 Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg 73 Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR 73 May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR 75 May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR 76 May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia 76 Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 77 Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Fibromyalgia, H1 2016 9 Number of Products under Development for Fibromyalgia - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Fibromyalgia - Pipeline by Astellas Pharma Inc., H1 2016 18 Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19 Fibromyalgia - Pipeline by Kineta, Inc., H1 2016 20 Fibromyalgia - Pipeline by Merck & Co., Inc., H1 2016 21 Fibromyalgia - Pipeline by Premier Biomedical Inc., H1 2016 22 Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2016 23 Fibromyalgia - Pipeline by Theravance Biopharma, Inc., H1 2016 24 Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 25 Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Assessment by Combination Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Fibromyalgia Therapeutics - Recent Pipeline Updates, H1 2016 58 Fibromyalgia - Dormant Projects, H1 2016 68 Fibromyalgia - Dormant Projects (Contd..1), H1 2016 69 Fibromyalgia - Discontinued Products, H1 2016 70



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify